-
公开(公告)号：US20240181021A1
公开(公告)日：2024-06-06
申请号：US18319821
申请日：2023-05-18
申请人： Inozyme Pharma, Inc.
发明人： Pedro Huertas , Deborah Wenkert
CPC分类号： A61K38/465 , A61P19/08 , C12N9/16 , C12Y301/04001 , C07K2319/30
摘要： The present disclosure provides, among other things, specific doses of an ENPP1 agent for in vivo treatment of an ENPP1 deficiency, such as for treatment of Generalized Arterial Calcification of Infancy (GACI), Autosomal Recessive Hypophosphatemic Rickets 2 (ARHR2), and other diseases resulting from pathological calcification, ENPP1 deficiency, ABCC6 deficiency such as diseases or disorders involving ectopic calcification of soft tissue in a subject.
-
公开(公告)号：US20220354933A1
公开(公告)日：2022-11-10
申请号：US17747379
申请日：2022-05-18
发明人： Yan YAN , Anumeha SHAH , Ashmita SAIGAL , Herman GRIFFIN , Susan Faas MCKNIGHT , Andre MAROZSAN , Kim ASKEW , Yvonne NITSCHKE , Frank RUTSCH
IPC分类号： A61K38/46 , A01K67/027
摘要： The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
-
公开(公告)号：US20210301268A1
公开(公告)日：2021-09-30
申请号：US17105245
申请日：2020-11-25
申请人： Inozyme Pharma, Inc.
发明人： Anthony Quinn , Alex J. Harvey , Zhinan Xia
摘要： The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and Pharmaceutical compositions comprising the fusion polypeptide.
-
公开(公告)号：US20230372455A1
公开(公告)日：2023-11-23
申请号：US18058715
申请日：2022-11-23
发明人： David Thompson , Frank Rutsch , Yvonne Nitschke
CPC分类号： A61K38/46 , A61P9/10 , A61K38/38 , C12Y306/01009 , A61L31/08 , A61L31/16 , C07K2319/30 , A61L2300/416 , A61L2300/254 , A61L2300/252
摘要： The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
-
公开(公告)号：US20230313158A1
公开(公告)日：2023-10-05
申请号：US18063263
申请日：2022-12-08
CPC分类号： C12N9/16 , C12Y301/04001 , A61P43/00
摘要： In certain aspects, the present invention provides novel soluble ENPP1 or ENPP3 polypeptides, as well as compositions and methods for using those variants to treat an indication associated an ENPP1 or ENPP3 deficiency. The compositions and methods provided herein are useful in treating diseases associated with an ENPP1 or ENPP3 deficiency such as pathological calcification or pathological ossification.
-
公开(公告)号：USRE49529E1
公开(公告)日：2023-05-16
申请号：US17111156
申请日：2020-12-03
申请人： Inozyme Pharma, Inc.
发明人： Anthony Quinn , Nelson Hsia , Tayeba Khan , Kim Lynette Askew , Gregory Grabowski , Zhiliang Cheng , W. Charles O'Neill
CPC分类号： A61K38/46 , A61P3/00 , A61P9/00 , A61P13/12 , C12N9/16 , C12Y301/04001 , C12Y306/01009 , C07K2319/30
摘要： The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
-
7.发明公开公开(公告)号：US20240016951A1
公开(公告)日：2024-01-18
申请号：US18148888
申请日：2022-12-30
发明人： Damon Banks , Catherine A. Nester , Edward Skolnik , Markus Walz , Frank Rutsch , Yvonne Nitschke
CPC分类号： A61K47/6815 , A61K38/465 , A61P7/04 , C12Y301/04001
摘要： The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
-
公开(公告)号：US20230330307A1
公开(公告)日：2023-10-19
申请号：US18058712
申请日：2022-11-23
CPC分类号： A61L31/047 , C07K17/06 , A61L2300/416 , A61L2300/254
摘要： The present disclosure provides compositions and methods for treating vascular smooth muscle cell proliferation in a subject that does not have a deficiency of ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) resulting in a pathological disease of calcification or ossification by administering an ENPP1 agent or an ENPP3 agent.
-
公开(公告)号：US20230129977A1
公开(公告)日：2023-04-27
申请号：US17819065
申请日：2022-08-11
申请人： Inozyme Pharma, Inc.
发明人： Anthony Quinn , Alex J. Harvey , Zhinan Xia
摘要： The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
-
公开(公告)号：US20240148907A1
公开(公告)日：2024-05-09
申请号：US18297228
申请日：2023-04-07
发明人： Steven Jungles , Demetrios Braddock
CPC分类号： A61K48/0058 , A61P19/08 , C12N9/14 , C12N9/16 , C12N15/86 , C12Y301/04001 , C12Y306/01009 , C07K2319/30 , C12N2750/14143 , C12N2750/14171 , C12N2830/008
摘要： The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.033 秒)
